Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesNeurology/NeurosurgeryBCBS Rhode Island TOMAC Coverage Update | OpenPaye…
    Ask Trek AI about this page
    DraftBlue Cross Blue Shield - Rhode IslandPolicy N/A

    Tonic Motor Activation (TOMAC) for Restless Legs Syndrome — Coverage Criteria

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts

    Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This draft policy governs coverage and coding for tonic motor activation (TOMAC), a bilateral peroneal nerve stimulation device for adults with primary moderate-to-severe restless legs syndrome (RLS) refractory to medication, and applies to Medicare Advantage and Commercial products of Blue Cross Blue Shield - Rhode Island.

    Policy Summary
    PayerBlue Cross Blue Shield - Rhode Island
    PolicyTonic Motor Activation (TOMAC) for Restless Legs Syndrome — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeDraft — no material changes
    Effective DateJun 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateFeb 18, 2026
    Key ActionVerify member benefits and eligibility via the provider call center before submitting claims.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Not coveredCoverage stance
    A4544, E0743Codes not covered
    InsufficientEvidence
    De NovoFDA status

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    14Refs

    Coverage determinations and policy stance

    Coverage determinations

    Medicare Advantage coverage stance: Tonic motor activation (TOMAC) for treatment of restless legs syndrome (RLS) refractory to medication is not covered because the evidence is insufficient to determine an improvement in net health outcome.

    From Medicare Advantage section

    Commercial coverage stance: Tonic motor activation (TOMAC) for treatment of restless legs syndrome (RLS) refractory to medication is not medically necessary because the evidence is insufficient to determine an improvement in net health outcome.

    From Commercial Products section

    Indication scope: TOMAC is a non–first-line treatment option indicated for adults with moderate-to-severe primary RLS that is refractory to pharmacologic therapy; first-line therapies include iron supplementation, gabapentinoids, and lifestyle modifications.

    Clinical pathway description

    The following CPT/HCPCS codes are identified for billing and adjudication purposes: A4544 — Electrode for external lower extremity nerve stimulator for restless legs syndrome; and E0743 — External lower extremity nerve stimulator for restless legs syndrome, each. These codes are not covered for Medicare Advantage Plans and are not medically necessary for Commercial Products under this policy.

    Services determined to be not medically necessary or otherwise non-covered may result in member financial responsibility. Providers may not charge the member for services that are non-covered or deemed not medically necessary unless the member has been informed and has agreed in writing in advance to assume financial responsibility. For member-specific benefits and eligibility, contact the provider call center and refer to the member’s subscriber agreement or employer agreement, which supersede this policy.

    For Commercial Products, tonic motor activation (TOMAC) as a treatment for restless legs syndrome refractory to medication is considered not medically necessary because the evidence is insufficient to demonstrate an improvement in net health outcome.

    Coding and billing guidance

    Not covered / Not medically necessary codesCPT | HCPCSNot Covered
    A4544Electrode for external lower extremity nerve stimulator for restless legs syndrome
    E0743External lower extremity nerve stimulator for restless legs syndrome, each

    Provider responsibilities, prior auth, and billing risk

    Prior Authorization

    Prior authorization: Not applicable — codes identified as not covered

    Prior authorization does not apply to this draft policy; however, the policy identifies CPT/HCPCS codes A4544 and E0743 as not covered or not medically necessary and these codes should be used when adjudicating claims.

    • Prior authorization: Not applicable per policy
    • Codes listed as not covered/not medically necessary: A4544, E0743
    Note

    Verify benefits and eligibility via provider call center

    Verify member benefits and eligibility with the provider call center before providing services; this policy does not guarantee payment and benefits are determined by the member's subscriber or employer agreement.

    • Contact the provider call center for member-specific benefits and eligibility
    • Member subscriber/employer agreement supersedes this policy

    Clinical background

    Restless legs syndrome (RLS) is a neurologic disorder characterized by an uncontrollable urge to move the legs and uncomfortable sensations that typically worsen at rest and during the evening or night, frequently disrupting sleep and often associated with periodic limb movements during sleep. First-line management includes addressing reversible contributors such as iron deficiency, implementing lifestyle modifications, and use of established pharmacologic therapies (for example, gabapentinoids and dopaminergic agents). Tonic motor activation (TOMAC) is a noninvasive neuromodulation approach that uses bilateral peroneal nerve stimulation via electrodes on the lower legs to activate the tibialis anterior muscles, producing sustained low-level contractions intended to mimic movement and reduce RLS symptoms. TOMAC is described as a non–first-line option for moderate-to-severe primary RLS that is refractory to pharmacologic therapy.

    Key definitions used in this policy

    Tonic motor activation (TOMAC) — device description and mechanism (bilateral peroneal nerve stimulation)
    Device typeBilateral peroneal nerve stimulation device with electrodes worn on the lower legs
    Stimulation targetCommon peroneal nerves located near the fibula in the lower legs
    Muscle activationActivates the tibialis anterior muscle to produce sustained, low-level contractions that mimic voluntary leg movements
    Delivery characteristicsBilateral high-frequency electrical stimulation delivered via surface electrodes
    Intended immediate effectMimics walking/stretching movements known to relieve RLS symptoms
    Refractory RLS — persistence despite first-line pharmacologic treatments
    Policy Summary
    PayerBlue Cross Blue Shield - Rhode Island
    PolicyTonic Motor Activation (TOMAC) for Restless Legs Syndrome — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeDraft — no material changes
    Effective DateJun 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateFeb 18, 2026
    Key ActionVerify member benefits and eligibility via the provider call center before submitting claims.
    SourceLink
    On This Page
    Coverage determinations and policy stanceCoding and billing guidanceProvider responsibilities, prior auth, and billing riskClinical backgroundKey definitions used in this policy
    Step Therapy

    Therapy sequencing: TOMAC is not first-line — use after pharmacologic therapy

    TOMAC is not a first-line therapy and should be considered only for moderate-to-severe primary RLS that is refractory to pharmacologic treatment after first-line therapies such as iron supplementation, gabapentinoids, and lifestyle modifications.

    • Indicated for moderate-to-severe primary RLS refractory to medication
    • First-line therapies include iron repletion, gabapentinoids, and lifestyle changes
    Step Therapy

    Step therapy: Not specified

    No step therapy requirements are specified in this policy.

    • The document does not define a required sequence of prior authorization steps or mandatory medication trials beyond stating TOMAC is not first-line.
    Documentation Required

    Benefits vary by group/contract — refer to EOC or Subscriber Agreement

    Benefits and coverage may vary by group or contract; refer to the member's Evidence of Coverage or Subscriber Agreement for applicable coverage specifics.

    • Policy is informational and not a guarantee of payment
    • Use Evidence of Coverage/Subscriber Agreement to determine not medically necessary benefits
    Documentation Required

    Call provider call center for member-specific benefits

    For member-specific benefits and eligibility, providers must call the provider call center and rely on the member's subscriber or employer agreement, which supersede the policy.

    • Call provider call center for member-specific information
    • Subscriber/employer agreement governs benefits and eligibility
    Denial Risk

    Denial risk: TOMAC claims (A4544, E0743) may be denied as not covered/not medically necessary

    Claims for TOMAC, including services billed with CPT/HCPCS codes A4544 and E0743, are subject to denial as not covered for Medicare Advantage or not medically necessary for Commercial Products because evidence is insufficient to demonstrate improved net health outcome.

    • Medicare Advantage: TOMAC not covered due to insufficient evidence
    • Commercial: TOMAC not medically necessary due to insufficient evidence
    • Not-covered codes: A4544, E0743
    Billing Rule

    Member financial responsibility risk for non-covered or not medically necessary services

    If services are determined to be not medically necessary or non-covered benefits, the provider may not charge the member unless the member was informed and agreed in writing in advance, which creates financial risk to the provider if not handled properly.

    • Do not bill the member for non-covered/not medically necessary services unless there is a prior written agreement
    • Refer to participation agreement provisions for billing rules
    DefinitionRLS that persists despite first-line treatments such as gabapentinoids, iron repletion, and other standard therapies
    When consideredConsidered when symptoms continue despite pharmacologic therapy and review of exacerbating factors
    Alternative strategiesMay prompt consideration of combination pharmacotherapy, low-dose opioids, behavioral interventions, and bilateral peroneal nerve stimulation
    Tonic Motor Activation (TOMAC) — noninvasive neuromodulation definition and intended symptom reduction
    DefinitionNoninvasive neuromodulation delivering high-frequency stimulation to the common peroneal nerves to evoke tonic leg muscle activation
    Physiologic rationaleEvokes afferent feedback to the central nervous system that may suppress abnormal sensory signals driving the urge to move
    Therapeutic goalReduce RLS symptoms by mimicking natural movement via sustained motor pathway activation
    Distinction from TENSTargets common peroneal motor pathways for tonic activation rather than superficial sensory nerves and pulsed pain-relief stimulation